Completed PHASE3 INTERVENTIONAL 2-arm NCT00211913

StaphVAX in Cardiovascular Surgery Patients

A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Safety and Immunogenicity of StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine, in Adult Patients Undergoing Cardiovascular Surgery

Sponsor: Nabi Biopharmaceuticals

Conditions Cardiovascular Diseases Cardiovascular Surgical Procedures Staphylococcal Infections

Interventions S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate placebo

Updated 6 times since 2017 Last updated: Dec 26, 2007 Started: Jun 30, 2004 Primary completion: Oct 31, 2005 Completion: Jan 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00211913, this PHASE3 trial focuses on Cardiovascular Diseases and Cardiovascular Surgical Procedures and remains completed. Sponsored by Nabi Biopharmaceuticals, it has been updated 6 times since 2004, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jun 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nabi Biopharmaceuticals

Data source: Nabi Biopharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Norfolk, United States